Nemesis Bioscience Overview

  • Founded
  • 2014
Founded
  • Status
  • Private
  • Employees
  • 6
Employees
  • Latest Deal Type
  • Early Stage VC
  • Latest Deal Amount
  • $86.8K
Latest Deal Amount
  • Investors
  • 8

Nemesis Bioscience General Information

Description

Developer of anti-microbial therapies designed to inactivate resistance in bacterial pathogens. The company's therapies develop Bacterial Cybergenetics for applications including the reversal of antibiotic resistance and for their clinical, veterinary and industrial delivery, enabling therapeutics to get existing antibiotics work again, prevent the spread of resistance genes and so also protect the efficacy of new antibiotics.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Pharmaceuticals
Other Industries
Biotechnology
Primary Office
  • Babraham Hall
  • Babraham Research Campus
  • Cambridge CB22 3AT
  • England, United Kingdom

Nemesis Bioscience Timeline

2018201920202021
Financing RoundCaptured Employee CountEstimated Employee Growth
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Nemesis Bioscience Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC 05-Feb-2019 $86.8K 00.00 00.000 Completed Generating Revenue
3. Early Stage VC 15-Jun-2018 00.000 00.000 00.000 Completed Generating Revenue
2. Seed Round 07-May-2017 $726K $1.19M 00.00 Completed Generating Revenue
1. Seed Round 15-Jun-2015 $465K $465K Completed Startup
To view Nemesis Bioscience’s complete valuation and funding history, request access »

Nemesis Bioscience Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Ordinary 000 00.000000 0000.00 0000.00 00 0000.00 0.000
A Preferred 0,000 00.000000 000.00 000.00 00 000.00 0.000
A Preferred 0,000 00.000000 0000.00 0000.00 00 0000.00 00.000
A Ordinary 0,000 00.000000 0000.00 0000.00 00 0000.00 0.00
A Preferred 3,120 $0.012979 $66.56 $66.56 1x $66.56 5.15%
Ordinary 9,180 $0.012979 $57.96 $57.96 1x $57.96 15.16%
To view Nemesis Bioscience’s complete cap table history, request access »

Nemesis Bioscience Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Developer of anti-microbial therapies designed to inactivate resistance in bacterial pathogens. The company's therapies
Pharmaceuticals
Cambridge, United Kingdom
6 As of 2020
00.00
0.000 0000-00-00
0000000000 0 00.00

00000000

ure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepteur
0000 000000000
Basel, Switzerland
00 As of 0000
000.00
000000000 000.00

0000000

irure dolor in reprehenderit in voluptate velit esse cillum dolore eu fugiat nulla pariatur. Excepte
0000000000000
Morristown, NJ
000 As of 0000
00000
0000 0000-00-00
000000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Nemesis Bioscience Competitors (30)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
BioVersys Venture Capital-Backed Basel, Switzerland 00 000.00 000000000 000.00
0000000 0000000000 Private Equity-Backed Morristown, NJ 000 00000 000000000000
0000 00000000000 Venture Capital-Backed Somerville, MA 0 00.00 00000000000 00.00
00000000 Formerly VC-backed Roseville, MN 00 000.00 000000&0 000.00
0000000 0000000000 Venture Capital-Backed Cambridge, MA 000 00000 00000000000 00000
You’re viewing 5 of 30 competitors. Get the full list »

Nemesis Bioscience Executive Team (3)

Name Title Board Seat Contact Info
Frank Massam Ph.D Co-Founder, Board Member and Chief Executive Officer
Conrad Lichtenstein Ph.D Co-Founder, Board Member and Chief Scientific Officer
Yoshikazu Mikawa Ph.D Co-Founder, Board Member and Chief Medical Officer
To view Nemesis Bioscience’s complete executive team members history, request access »

Nemesis Bioscience Board Members (5)

Name Representing Role Since
Alastair Riddell Nemesis Bioscience Board Member 000 0000
Conrad Lichtenstein Ph.D Nemesis Bioscience Co-Founder, Board Member and Chief Scientific Officer 000 0000
Frank Massam Ph.D Nemesis Bioscience Co-Founder, Board Member and Chief Executive Officer 000 0000
Simon Sturge Self Chairman 000 0000
Yoshikazu Mikawa Ph.D Nemesis Bioscience Co-Founder, Board Member and Chief Medical Officer 000 0000
To view Nemesis Bioscience’s complete board members history, request access »

Nemesis Bioscience Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %ile
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Nemesis Bioscience Investors (8)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Coastal International Holdings Corporation Minority 000 0000 000000 0
Shionogi & Co. Corporation Minority 000 0000 000000 0
Wren Capital Angel Group Minority 000 0000 000000 0
Innovate UK Government Minority 000 0000 000000 0
Mark Mccamish Angel (individual) Minority 000 0000 000000 0
You’re viewing 5 of 8 investors. Get the full list »